<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04750252</url>
  </required_header>
  <id_info>
    <org_study_id>StroMel-01</org_study_id>
    <nct_id>NCT04750252</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of StroMel™ in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint</brief_title>
  <official_title>An Open Label Study to Evaluate Safety and Tolerability of StroMel™ in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akan Biosciences, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akan Biosciences, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to evaluate the safety and tolerability of autologous StroMel™ for&#xD;
      the treatment of moderate to severe OA of the knee joint.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 22, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of StroMel in subjects with moderate to severe OA of the kneee</measure>
    <time_frame>12 months</time_frame>
    <description>Presence of adverse events in less than 10% of the study population. Adverse events assessed will be Grade 4 administrative site infection, Grade 3 hypersensitivity/anaphylaxis, &gt;20% increase in WOMAC pain score, treatment-related disability, and presence of tumors post-treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Safety of StroMel</measure>
    <time_frame>12 months</time_frame>
    <description>Summary of all study related AEs and SAEs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of StroMel in managing OA of the knee</measure>
    <time_frame>52 weeks</time_frame>
    <description>Reduction of NSAIDS, until study completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of StroMel in assessment of OA of the knee post-treatment</measure>
    <time_frame>52 weeks</time_frame>
    <description>Percent change from baseline in rating scales (WOMAC and VAS assessments)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Osteo Arthritis Knee</condition>
  <arm_group>
    <arm_group_label>Subjects with moderate to severe OA of the Knee</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>StroMel</intervention_name>
    <description>Autologous MSC</description>
    <arm_group_label>Subjects with moderate to severe OA of the Knee</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults between the ages of 25-65 years&#xD;
&#xD;
          2. Body Mass Index (BMI) less than 40 kg/m2&#xD;
&#xD;
          3. Ambulatory and in good general health as described by vital signs (blood pressure&#xD;
             90/60 mm Hg to 120/80 mm Hg, pulse rate 60-100 beats per minute, temperature 97.2-99.1&#xD;
             °F) and normal blood chemistry.&#xD;
&#xD;
          4. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain score of ≥&#xD;
             11 (worst possible = 20) over the previous 7 days&#xD;
&#xD;
          5. OA of the knee with Kellgren and Lawrence radiographic classification (Grade 2-4&#xD;
             inclusive) within the last 6 months&#xD;
&#xD;
          6. Minimum score of 40 out of possible 100 on the VAS (Visual Analog Scale) for pain.&#xD;
&#xD;
          7. Patients who have failed to adequately respond for at least 6 months to at least 2 OA&#xD;
             therapies that include conservative, non-pharmacological therapy and simple analgesics&#xD;
             (e.g., acetaminophen); nonsteroidal anti-inflammatory drugs (NSAIDS); avoidance of&#xD;
             activities that cause joint pain; exercise; weight loss; physical therapy; and removal&#xD;
             of excess fluid from the knee.&#xD;
&#xD;
          8. Have suitable knee joint anatomy for intra-articular injection.&#xD;
&#xD;
          9. For adults of reproductive potential: use of effective contraception for at least 1&#xD;
             month prior to screening and agreement to use such a method during study&#xD;
             participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis,&#xD;
             or arthritis associated with inflammatory bowel disease.&#xD;
&#xD;
          2. Subject with an infection that requires parenteral antibiotic administration.&#xD;
&#xD;
          3. Active infection or crystal disease in the index joint within 1 month of screening&#xD;
&#xD;
          4. History of fracture in the index limb, joint instability, or history of acute&#xD;
             dislocation within 12 months of screening, or fracture with sequelae at any time&#xD;
&#xD;
          5. Intra-articular treatment of any joint with any of the following agents within 6&#xD;
             months of screening: Any corticosteroid preparation (investigational or marketed),&#xD;
             sodium hyaluronate, any biologic agent (e.g., platelet rich plasma (PRP) injection,&#xD;
             stem cells, prolotherapy, amniotic fluid injection); investigational six months prior&#xD;
             to enrollment.&#xD;
&#xD;
          6. Presence of surgical hardware or other foreign body in the index joint&#xD;
&#xD;
          7. Subjects who were administered with immunosuppressants such as cyclosporin A or&#xD;
             azathioprine within 6 weeks before screening.&#xD;
&#xD;
          8. Planned or anticipated surgery of the joint during the study period&#xD;
&#xD;
          9. Allergies to anesthesia&#xD;
&#xD;
         10. Subjects who tested positive for HIV, HCV, WNV, CMV, HBV, HTLV, ZIKA, syphilis, flu or&#xD;
             COVID-19. Note: CMV is not a relevant communicable disease agent. A subject who tests&#xD;
             positive or reactive for CMV is not necessarily ineligible. Physicians will determine&#xD;
             donor eligibility for subjects with positive CMV test results.&#xD;
&#xD;
         11. History of lipid disorders: lipedema, lipomatosis, or lipodystrophies.&#xD;
&#xD;
         12. Active cancer, chemotherapy, or other malignancies in the last 6 months.&#xD;
&#xD;
         13. Recent history of DVT or pulmonary embolism requiring anticoagulants or other&#xD;
             medicines per the hematologist.&#xD;
&#xD;
         14. Subject who participated in another clinical trial within 3 months before the&#xD;
             screening visit&#xD;
&#xD;
         15. Any illness which, in the Investigator's judgment, will interfere with the subject's&#xD;
             ability to comply with the protocol, compromise patient safety, or interfere with the&#xD;
             interpretation of the study results.&#xD;
&#xD;
         16. Subjects who are breastfeeding&#xD;
&#xD;
         17. Subjects with uncontrolled arrhythmias&#xD;
&#xD;
         18. Subjects with hemophilia; factor II, V, VII, X, or XII deficiencies; or Von&#xD;
             Willebrand's disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mukesh C Kumar</last_name>
    <phone>2407504893</phone>
    <email>mkumar@fdamap.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Akan Biosciences, LLC</name>
      <address>
        <city>Germantown</city>
        <state>Maryland</state>
        <zip>20876</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Mukesh Kumar, PhD</last_name>
      <phone>240-750-4893</phone>
      <email>mkumar@fdamap.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stem cell, MSC, autologous, adipose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

